A Phase II, Randomized, Open-Label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-Line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2014
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha-2a
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms CONCERT
- Sponsors Bayer; Bayer HealthCare
- 10 Jun 2017 Biomarkers information updated
- 24 Mar 2012 This trial is recruiting in Spain and France.
- 10 Sep 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.